What is ICD-10 code C83.5A?

C83.5A is the ICD-10-CM diagnosis code for Lymphoblastic (diffuse) lymphoma, in remission. Lymphoblastic lymphoma that is currently in remission, meaning the cancer is no longer detectable or has responded well to treatment. It belongs to the ICD-10-CM chapter for neoplasms (c00-d49). C83.5A is a billable code, meaning it can be reported on a claim as a primary or secondary diagnosis when supported by documentation. C83.5A is part of the FY2026 ICD-10-CM code set published by the CMS National Center for Health Statistics and used on Medicare, Medicaid, and commercial claims in the United States.

Yes. C83.5A is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. C83.5A is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

What is the V28 vs V24 difference for C83.5A?

CMS phased in the V28 risk adjustment model over payment years 2024 (33%), 2025 (67%), and 2026 (100%), replacing V24. V28 consolidates HCC categories, removes some lower-acuity conditions, and recalibrates RAF weights across the entire model. For C83.5A, V28 maps to Lung and Other Severe Cancers at RAF 1.136 while V24 mapped to Lymphoma and Other Cancers at RAF 0.675. Both models can still appear in legacy data and in payer-specific lookback periods.

What should coders know when reporting C83.5A?

This code should only be used when documentation explicitly states the patient is in remission or has achieved complete response Ensure remission status is clearly documented in clinical notes; do not assume remission without explicit statement Because C83.5A maps to a payment HCC, the documentation must also satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's risk adjustment score.

2026 ICD-10-CM C83.5A: Lymphoblastic (diffuse)

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC83.5AEffective periodFY2026 Apr Update (Apr 1-Sep 30)

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C83.5A

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Lymphoblastic (diffuse) lymphoma, in remission

Lymphoblastic lymphoma that is currently in remission, meaning the cancer is no longer detectable or has responded well to treatment.

Buddy Insight

Lymphoblastic lymphoma in remission indicates the patient has achieved treatment response following intensive chemotherapy.

CMS-HCC V28

Mapped

HCC 20

Lung and Other Severe Cancers

RAF 1.136

CMS-HCC V24

Mapped

HCC 10

Lymphoma and Other Cancers

RAF 0.675

ACA/HHS

Mapped

HCC 10

HHS-HCC 10

Varies by metal level

ESRD/PACE

Mapped

HCC 10

Lymphoma and Other Cancers

RAF 0.111

RXHCC

Mapped

HCC 21

Hodgkin Lymphoma and Other Ca...

RAF 0.410

Code Book Path

Official

C83Non-follicular lymphoma

C83.5Lymphoblastic (diffuse) lymphoma

C83.5ALymphoblastic (diffuse) lymphoma, in remission

Inclusion Terms

Official

B-precursor lymphoma
Lymphoblastic B-cell lymphoma
Lymphoblastic lymphoma NOS
Lymphoblastic T-cell lymphoma
T-precursor lymphoma

Excludes 2

Official

ICD-10-CM does not list Excludes 2 notes for C83.5A in this effective period.

Related Child Codes

Official

C83.50Lymphoblastic (diffuse) lymphoma, unspecified site

C83.51Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck

C83.52Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes

C83.53Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes

C83.54Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb

Includes

Official

ICD-10-CM does not list Includes notes for C83.5A in this effective period.

Excludes 1

Official

ICD-10-CM does not list Excludes 1 notes for C83.5A in this effective period.

Code First

Official

ICD-10-CM does not list Code First sequencing instructions for C83.5A in this effective period.

Use Additional

Official

ICD-10-CM does not list Use Additional Code instructions for C83.5A in this effective period.

Code Also

Official

ICD-10-CM does not list Code Also instructions for C83.5A in this effective period.

Buddy Documentation Tip

HCC Buddy guidance

Explicit provider documentation of complete remission

End-of-treatment imaging showing no evidence of disease

Bone marrow biopsy confirming no residual disease

Date remission was achieved

MEAT Support

HCC Buddy guidance

Explicit provider documentation of complete remission

End-of-treatment imaging showing no evidence of disease

Bone marrow biopsy confirming no residual disease

Date remission was achieved

Audit Caution

HCC Buddy guidance

Continuing to code active disease when remission is documented

Prematurely assigning personal history code during active surveillance

Using remission code during relapse; revert to active disease code

Confusing with ALL remission code if the original diagnosis was leukemia

Common Mistakes

HCC Buddy guidance

C83.50 — Active lymphoblastic lymphoma, unspecified; do not use when remission is documented

Z85.79 — Personal history of lymphoid malignancy; use only after active surveillance has ended

C83.51-C83.59 — Active site-specific codes; replace with C83.5A when remission is achieved

C91.01 — Acute lymphoblastic leukemia in remission; if originally classified as leukemia, maintain leukemia code

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is C83.5A an HCC code?

Yes. C83.5A (Lymphoblastic (diffuse) lymphoma, in remission) maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24), with a community non-dual aged RAF of 1.136. It is billable for payment year 2026.

Coder answer: C83.5A is billable and maps to V28 HCC 20, Lung and Other Severe Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code: C83.5A
Description: Lymphoblastic (diffuse) lymphoma, in remission
HCC (V28): HCC 20 — Lung and Other Severe Cancers
RAF: 1.136
Billable: Yes
Payment year: 2026

HCC Category Mapping

V28HCC 20, Lung and Other Severe Cancers

1.136

V24HCC 10, Lymphoma and Other Cancers

0.675

ESRDHCC 10, Lymphoma and Other Cancers

0.111

RxHCCHCC 21, Hodgkin Lymphoma and Other Cancers

0.410

Each model's RAF is its CMS base weight for that model's standard population, so weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.

Work C83.5A in the Code Book — tabular path, V28 RAF, and MEAT checklist →

MEAT Criteria for C83.5A

For C83.5A to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.

MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
EEvaluate: test results, medication response, or physical findings reviewed by the provider
AAssess: explicit mention in the assessment or plan with acknowledgment of status
TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C83.5A during that encounter, not just copy-forwarded from a problem list.

Coder workflow notes

Get the V28 RAF + MEAT cheat sheet

One printable page: confirm a code's V28 HCC status, its RAF weight, and the MEAT your note needs to make it stick. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

C83.5A is the ICD-10-CM diagnosis code for lymphoblastic (diffuse) lymphoma, in remission. Lymphoblastic lymphoma that is currently in remission, meaning the cancer is no longer detectable or has responded well to treatment. C83.5A sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C83.5A maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 1.136. Under the older CMS-HCC V24 model, C83.5A maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.

This code should only be used when documentation explicitly states the patient is in remission or has achieved complete response. Because C83.5A maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C83.5A sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

•This code should only be used when documentation explicitly states the patient is in remission or has achieved complete response
•Ensure remission status is clearly documented in clinical notes; do not assume remission without explicit statement

Clinical Significance

Lymphoblastic lymphoma in remission indicates the patient has achieved treatment response following intensive chemotherapy. Given the aggressive nature and treatment intensity (similar to acute leukemia protocols), remission documentation is particularly important for ongoing surveillance and risk adjustment. Relapse surveillance typically continues for several years.

Documentation Requirements

✓Explicit provider documentation of complete remission
✓End-of-treatment imaging showing no evidence of disease
✓Bone marrow biopsy confirming no residual disease
✓Date remission was achieved
✓Surveillance plan and schedule for relapse monitoring

Commonly Confused Codes

•C83.50: Active lymphoblastic lymphoma, unspecified; do not use when remission is documented
•Z85.79: Personal history of lymphoid malignancy; use only after active surveillance has ended
•C83.51-C83.59: Active site-specific codes; replace with C83.5A when remission is achieved
•C91.01: Acute lymphoblastic leukemia in remission; if originally classified as leukemia, maintain leukemia code